Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04145219 · ClinicalTrials.gov registry record · Phase 3
House Dust Mite Allergy Trial In Children
A Phase 3 study, sponsored by ALK-Abelló A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,460
- Enrollment target
NCT04145219: Completed Phase 3 study, sponsored by ALK-Abelló A/S.
NCT04145219 is a Phase 3 study that has completed, run by ALK-Abelló A/S. The registered enrollment target is 1,460 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04145219, a Phase 3 study, has completed, sponsored by ALK-Abelló A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,460 participants
- Enrollment target
Study Summary
A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust mites (MATIC)
Primary Outcome
The primary endpoint in the trial was the average daily total combined rhinitis symptoms and medication score (TCRS) during the primary efficacy assessment period. The average daily TCRS evaluates the treatment effect based on the reduction in daily rhinitis symptoms and medication score (on a scale of 0-24). Higher scores indicate more severe symptoms and/or more use of rhinitis medication. The endpoint is calculated as the average score of all reported daily values during the 8-week primary ef
Interventions
- OTHER Placebo
- BIOLOGICAL Sublingual allergy immunotherapy tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,460 participants |
| Start Date | 2019-10-12 |
| Est. Completion | 2023-04-21 |
| Phase | Phase 3 |
What the finished NCT04145219 record still lists
NCT04145219 is an interventional study that assigns participants to a tested intervention. Its 1,460 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04145219 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04145219 about?
NCT04145219 is a clinical study titled "House Dust Mite Allergy Trial In Children". A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust mites (MATIC)
What is the current status of trial NCT04145219?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,460 participants. The study started on 2019-10-12. Estimated completion is 2023-04-21.
What interventions are being tested in trial NCT04145219?
The interventions under investigation include: Placebo (OTHER), Sublingual allergy immunotherapy tablet (BIOLOGICAL).
Who is sponsoring clinical trial NCT04145219?
This trial is sponsored by ALK-Abelló A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04145219's enrollment target sits among peer trials
1,460 164th of 2000 higher than 1,837 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI